MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 146 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.91 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $1,947,256 | +14.4% | 7,292 | -0.8% | 0.01% | 0.0% |
| Q4 2023 | $1,701,569 | +71.4% | 7,354 | +8.2% | 0.01% | +16.7% |
| Q3 2023 | $992,488 | -34.5% | 6,796 | +3.7% | 0.01% | -33.3% |
| Q2 2023 | $1,514,205 | +1.7% | 6,555 | +6.7% | 0.01% | -10.0% |
| Q1 2023 | $1,488,688 | -14.8% | 6,145 | +2.0% | 0.01% | -16.7% |
| Q4 2022 | $1,747,886 | +344.8% | 6,022 | -0.4% | 0.01% | +300.0% |
| Q3 2022 | $393,000 | -7.7% | 6,044 | +1.4% | 0.00% | 0.0% |
| Q2 2022 | $426,000 | -25.8% | 5,958 | +1.9% | 0.00% | 0.0% |
| Q1 2022 | $574,000 | +8.3% | 5,845 | -6.6% | 0.00% | 0.0% |
| Q4 2021 | $530,000 | +6.9% | 6,257 | +0.7% | 0.00% | 0.0% |
| Q3 2021 | $496,000 | -20.0% | 6,214 | -2.3% | 0.00% | +50.0% |
| Q2 2021 | $620,000 | +4.0% | 6,362 | +24.8% | 0.00% | 0.0% |
| Q1 2021 | $596,000 | +5.5% | 5,099 | +0.3% | 0.00% | 0.0% |
| Q4 2020 | $565,000 | -9.0% | 5,085 | -2.8% | 0.00% | -33.3% |
| Q3 2020 | $621,000 | +2.5% | 5,231 | -2.2% | 0.00% | 0.0% |
| Q2 2020 | $606,000 | +69.7% | 5,350 | +0.1% | 0.00% | +50.0% |
| Q1 2020 | $357,000 | -20.0% | 5,342 | +9.2% | 0.00% | 0.0% |
| Q4 2019 | $446,000 | +4.9% | 4,893 | -0.8% | 0.00% | 0.0% |
| Q3 2019 | $425,000 | -18.4% | 4,934 | -0.7% | 0.00% | 0.0% |
| Q2 2019 | $521,000 | -6.0% | 4,969 | +12.3% | 0.00% | 0.0% |
| Q1 2019 | $554,000 | +7.6% | 4,424 | -3.2% | 0.00% | 0.0% |
| Q4 2018 | $515,000 | -47.8% | 4,568 | -0.8% | 0.00% | -33.3% |
| Q3 2018 | $986,000 | -6.9% | 4,603 | +21.6% | 0.00% | -25.0% |
| Q2 2018 | $1,059,000 | +200.0% | 3,785 | +25.2% | 0.00% | +300.0% |
| Q1 2018 | $353,000 | +37.4% | 3,022 | +8.0% | 0.00% | 0.0% |
| Q4 2017 | $257,000 | +110.7% | 2,797 | +3.2% | 0.00% | – |
| Q3 2017 | $122,000 | +197.6% | 2,710 | +8.1% | 0.00% | – |
| Q2 2017 | $41,000 | – | 2,508 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paulson & Co. | 1,850,000 | $518,296,000 | 38.31% |
| Tao Capital Management LP | 130,529 | $36,569,005 | 29.98% |
| University of Wisconsin Foundation | 45,730 | $12,811,717 | 14.42% |
| AlpInvest Partners B.V. | 84,595 | $23,700,135 | 8.50% |
| RTW INVESTMENTS, LP | 1,915,862 | $536,747,898 | 8.31% |
| Propel Bio Management, LLC | 43,032 | $12,055,845 | 7.82% |
| Avoro Capital Advisors LLC | 2,055,555 | $575,884,289 | 7.67% |
| Baker Brothers Advisors | 1,974,590 | $553,201,134 | 7.07% |
| Tri Locum Partners LP | 65,352 | $18,309,016 | 4.63% |
| TCG Crossover Management, LLC | 149,283 | $41,823,125 | 4.36% |